SHigh-throughput Screening
Genetic and small-molecule screens — including CRISPR-based functional genomics — to find combination strategies, resistance mechanisms, and novel targets in PDAC.
What We Do
Research Programs
Five interconnected pillars — the sPARK acronym — driving translational breakthroughs in pancreatic ductal adenocarcinoma (PDAC).
PPOLQ & Synthetic Lethality
Polymerase theta (POLQ) and error-prone end-joining as a source of synthetic lethal vulnerabilities in HRD-deficient tumors.
ANeoantigens & Biologics
Pipelines for neoantigen discovery and biologic modalities targeting tumor-specific epitopes.
RDNA Damage Repair & PARP-Immunotherapy
Combining DNA-damage-repair targeting with immunotherapy in BRCA/PALB2-mutated and HRD pancreatic cancer.
Nature Medicine 2026
KKRAS-driven Vulnerabilities
Targeting KRAS G12D — the most common variant in PDAC — with first-in-class degraders and RAS(ON) inhibitors.
NEJM 2026